Table 1—

Selected characteristics at baseline among women with and without type 2 diabetes by treatment group

Diabetic women
Nondiabetic women
ALNPlaceboALNPlacebo
n1481493,0873,074
Age at randomization (years)69.3 ± 6.169.5 ± 5.968.5 ± 6.268.7 ± 6.1
White race95.397.397.097.0
BMI (kg/m2)27.3 ± 5.126.9 ± 5.225.0 ± 3.925.1 ± 4.0
Years since menopause23.2 ± 8.623.0 ± 8.021.1 ± 8.521.3 ± 8.5
Lumbar spine BMD (g/cm2)0.88 ± 0.150.86 ± 0.140.82 ± 0.130.82 ± 0.14
Total hip BMD (g/cm2)0.71 ± 0.090.70 ± 0.0890.69 ± 0.090.69 ± 0.09
BSAP (units/l)14.4 ± 5.113.5 ± 4.713.6 ± 4.313.8 ± 4.5
NTx (μg/l)43.2 ± 17.644.9 ± 17.251.8 ± 20.652.0 ± 19.9
CTx (pmol/l)3,096.7 ± 2,755.32,773.1 ± 1,287.53,337.3 ± 1,757.33,338.8 ± 1,646.1
Morphometric prevalent vertebral fracture29.732.231.731.1
Health status excellent or very good46.652.466.764.6
Participate in a regular activity program42.638.346.547.8
Days stayed in bed because of an injury/illness 12 months before baseline
 1–3 days25.014.819.419.0
 ≥3 days*4.16.73.52.4
Days cut down on usual activities because of injury/illness 12 months before baseline
 1–10 days18.29.411.912.5
 ≥10 days*18.213.414.113.2
Ever use estrogen since menopause47.335.641.740.4
Type of hypoglycemic medication
 Insulin8.16.7
 Oral22.319.5
Age of diabetes diagnosis (years)57.5 ± 13.555.4 ± 14.5
Duration of diabetes (years)11.4 ± 12.314.9 ± 14.2
  • Data are means ± SD or percent.

  • *

    * Median value based on the distribution of entire cohort.

  • P < 0.1 for comparison of ALN and placebo groups in women with diabetes.